High-dose enoximone to evaluate reversibility of pulmonary hypertension: Is there a diagnostic value of neurohormonal measurements?

American Heart Journal

Volumn 137, Issue 5, 1999, Pages 887-894

  Schulz, Olaf ^a   Mitrovic, Veselin ^b   Schönburg, Markus ^b   Thormann, Jochen ^b  

^a Heinrich Mann Hosp for Cardiac R   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ALDOSTERONE; ANGIOTENSIN; ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE; ENDOTHELIN 1; ENOXIMONE; NORADRENALIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; FEMALE; HEART FAILURE; HEART HEMODYNAMICS; HEART OUTPUT; HEART TRANSPLANTATION; HORMONE BLOOD LEVEL; HUMAN; MALE; NEUROENDOCRINE SYSTEM; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION;

EID: 0032954920     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(99)70413-8     Document Type: Article

References (30)

1. 1. Rundquist B, Elam M, Eisenhofer G, et al. Normalization of total body and regional sympathetic hyperactivity in heart failure after heart transplantation. J Heart Lung Transplant 1996;15:516-26.
2. 2. James KB, McCarthy PM, Betkowski A, et al. Course of neurohormones from heart failure to left ventricular assist device to cardiac transplantation. J Am Coll Cardiol 1996;27(suppl A):341 A, 996-3.
3. 3. James KB, McCarthy PM, Jaalouk S, et al. Plasma volume and its regulatory factors in congestive heart failure after implantation of long-term left ventricular assist devices. Circulation 1996;93:1515-9.
4. 4. Estrada-Quintero T, Uretsky BF, Murali S, et al. Neurohormonal activation and exercise function in patients with severe heart failure and patients with left ventricular assist system. Chest 1995;107:1499-503.
5. 5. Thormann J, Hueting J, Kremer P, et al. Enoximone: true inotropic effects? Do they cause ischemia? Analysis of end-systolic pressure-volume relations using the conductance (volume) catheter technique. Cardiovasc Drugs Ther 1990;4:1403-16.
6. 6. Erbel R, Meyer J, Diefenbach C, et al. A dose-response study of intravenous enoximone in congestive heart failure. Am J Cardiol 1987;59:31C-36C.
7. 7. Tsutamoto T, Wada A, Maeda Y, et al. Relation between endothelin-1 spillover in the lungs and pulmonary vascular resistance in patients with chronic heart failure. J Am Coll Cardiol 1994;23:1427-33.
8. 8. Cargill RI, Lipworth BJ. Pulmonary vasorelaxant activity of atrial natriuretic peptide and brain natriuretic peptide in humans. Thorax 1995;50:183-5.
9. 9. Itoh H, Pratt RE, Dzau V. Atrial natriuretic peptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990;86:1690-7.
10. 10. Morrell NW, Morris KG, Stenmark KR. Role of angiotensin-converting enzyme and angiotensin II in development of hypoxic pulmonary hypertension. Am J Physiol 1995;269:H1186-94.
11. 11. Yao S, Ramires FJA, Weber KT. Fibrosis of atria and great vessels in response to angiotensin and aldosterone infusion. Circulation 1996;84(suppl):655, 3851.
12. 12. Ryan W, Ryan US, Schultz DR, et al. Subcellular localization of pulmonary angiotensin-converting enzyme (kininase II). Biochem J 1975;146:4979.
13. 13. Zannad F. Aldosterone and heart failure. Eur Heart J 1995;16(suppl N):98-102.
14. 14. Goldring RM, Turino GM, Cohen G, et al. The catecholamines in the pulmonary arterial pressor response to acute hypoxia. J Clin Invest 1962;41:1211.
15. 15. Blacher J, Amah G, Girerd X, et al. Association between increased plasma levels of aldosterone and decreased systemic arterial compliance in subjects with essential hypertension. Am J Hypertens 1997;10:1326-34.
16. 16. Packer M. Evolution of the neurohumoral hypothesis to explain the progression of chronic heart failure. Eur Heart J 1995; 16(suppl F):4-6.
17. 17. Nootens M, Kaufmann E, Rector T, et al. Neurohumoral activation in patients with right ventricular failure from pulmonary hypertension: Relation to hemodynamic variables and endothelin levels. J Am Coll Cardiol 1995;26:1581-5.
18. 18. Nootens M, Kaufmann E, Toher C, et al. Neurohumoral activity in primary pulmonary hypertension. Circulation 1993;88(suppl I):1-109, 0573.
19. 19. Urata H, Nishimura H, Ganten D. Mechanisms of angiotensin II formation in humans. Eur Heart J 1995;16(suppl N):79-85.
20. 20. Edwards BS, Zimmermann RS, Schwab TR, et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic peptide. Circ Res 1988;62:191-5.
21. 21. Creager MA, Hirsch AT, Nabel EG, et al. Responsiveness of atrial narriuretic factor to reduction in right atrial pressure in patients with chronic congestive heart failure. J Am Coll Cardiol 1988;11:1191-8.
22. 22. Lewis BS, Makhoul N, Dakak N, et al. Atrial narriuretic peptide in severe heart failure: response to controlled changes in atrial pressures during intravenous nitroglycerin therapy. Am Heart J 1992;124:1009-16.
23. 23. Iervasi G, Clerico A, Berti S, et al. ANP kinetics in normal men: in vivo measurement by a tracer method, and correlation with sodium intake. Am J Physiol 1993;264:F480-9.
24. 24. Kuroski-de Bold ML, de Bold AJ. Stretch-secretion coupling in atrial cardiocytes: dissociation between atrial natriuretic factor release and mechanical activity. Hypertension 1991;18(suppl III):III-169-78.
25. 25. Moe GW, Grima EA, Wong NLM, et al. Plasma and cardiac tissue atrial and brain natriuretic peptides in experimental heart failure. J Am Coll Cardiol 1996;27:720-7
26. 26. Berti S, Palmieri C, Ravani M, et al. Acute enoximone effect on systemic and renal hemodynamics in patients with heart failure. Cardiovasc Drugs Ther 1996;10:81-7.
27. 27. Williams RE, Field ME, Buffer SA, et al. Regional increases in ventricular atrial natriuretic factor mRNA after myocardial infarction: a role for mechanical overload in adjacent zone dysfunction. Circulation 1995;92(suppl I):I-658, 3161.
28. 28. Lin X, Hänze J, Heese F, et al. Gene expression of natriuretic peptide receptors in myocardial cells. Circ Res 1995;77:750-8.
29. 29. Mitrovic V, Neuzner J, Opper H, et al. Neurohumorale und hämodynamische Effekte in der Kombinationstherapie von Enoximon und Dopamin. Z Kardiol 1994;83:37-48.
30. 30. Mitrovic V, Weber M, Bandow J, et al. Auswirkungen von niedrig dosiertem Dopamin auf Hämodynamik, Plasmakatecholamine, alpha2-und beta2-Rezeptoren bei Patienten mit Herzinsuffizienz. Herz/Kreisl 1993;25:248-54.